Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMS)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended June 30, 2026
Business Overview: BMS operates as a single segment focused on the discovery, development, and commercialization of innovative medicines in oncology, hematology, immunology, cardiovascular, and neuroscience. The company manages resources at a corporate level rather than by product franchise.
Key Financial Metrics
| Metric (Dollars in Millions) | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Total Revenues | $12,973 | $12,269 | $24,462 | $23,470 |
| Net Earnings Attributable to BMS | $3,317 | $1,310 | $5,994 | $3,766 |
| Diluted EPS (GAAP) | $1.62 | $0.64 | $2.93 | $1.85 |
| Diluted EPS (Non-GAAP) | $2.04 | $1.46 | $3.62 | $3.26 |
| Operating Cash Flow (YTD) | $4,497 | $5,871 | $4,497 | $5,871 |
| Net Debt Position | ($31,656) | N/A | ($31,656) | ($34,043) |
| Cash & Marketable Securities | $11,464 | N/A | $11,464 | $11,069 |
Note: Net Debt is calculated as Total Debt less Cash, Cash Equivalents, and Marketable Debt Securities. Negative values indicate a net cash position.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 6% in Q2 2026 and 4% year-to-date compared to 2025. Growth was driven by the Growth Portfolio (up 15% in Q2) and Eliquis (up 22% in Q2), partially offset by declines in the Legacy Portfolio due to generic erosion (Revlimid down 49%, Pomalyst down 71%).
- Profitability Surge: Net earnings attributable to BMS more than doubled in Q2 2026 ($3.3B vs $1.3B). This was primarily due to the absence of a $1.5 billion one-time Acquired IPRD charge recorded in Q2 2025 related to the BioNTech collaboration, lower amortization of acquired intangible assets, and higher revenues.
- Expense Trends:
- R&D Expenses: Increased 15% in Q2 2026 ($2.96B) due to $420 million in IPRD impairment charges and a $220 million priority review voucher purchase.
- Amortization: Decreased 47% in Q2 2026 ($437M vs $830M) as the Pomalyst acquired marketed product right was fully amortized in late 2025.
- Other Income/Expense: Shifted from a $494M expense in Q2 2025 to a $61M income in Q2 2026, driven by the loss of royalty income from the terminated diabetes business and gains on equity investments.
- Cash Flow: Operating cash flow decreased $1.4 billion year-to-date, primarily due to lower net customer receipts following a list price reduction for Eliquis in the U.S.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Pipeline Progress: Significant developments include FDA acceptance of NDAs for iberdomide and mezigdomide, positive interim Phase II results for pumitamig (NSCLC), and EC/FDA approvals for Opdivo (cHL) and Sotyktu (PsA).
- Strategic Initiatives: BMS expects to realize approximately $2.0 billion in annual cost savings by the end of 2027 through its ongoing strategic productivity initiative.
- Business Development: Entered a global strategic collaboration with Hengrui in May 2026 for 13 early-stage assets, involving a $600 million upfront payment and up to $14.3 billion in milestones.
Risks and Contingencies
- Governmental Pricing Pressure: The Inflation Reduction Act (IRA) has set "maximum fair prices" for Eliquis (effective Jan 2026) and Pomalyst (effective Jan 2027). Orencia was selected for price negotiation starting in 2028. BMS is litigating the constitutionality of the IRA drug-pricing program, though the Supreme Court denied certiorari in May 2026.
- Patent Litigation: Active litigation regarding generic entry for Eliquis in Europe and the U.S. (Azurity Pharmaceuticals). Generics have entered the market in the UK and Poland. BMS is also defending against patent challenges for Camzyos and Orencia.
- Legal Proceedings: Ongoing Celgene Securities Litigation (settlement approved May 2026) and Contingent Value Rights (CVR) Litigations regarding the Mirati acquisition. BMS is also involved in pricing and promotional practices litigation (Plavix Texas Litigation) and 340B program disputes.
Investor Verification Checklist
- IPRD Impairments: Verify the specific clinical assets written down in the $830 million YTD impairment charge and the impact on future R&D pipelines.
- Eliquis Pricing Impact: Assess the long-term revenue trajectory of Eliquis following the U.S. list price reduction and the implementation of IRA "maximum fair prices."
- Generic Erosion: Monitor the volume and market share impact of generic entry for Revlimid, Pomalyst, and Sprycel in the U.S. and EU.
- Legal Resolutions: Track the status of the CVR Litigations and the outcome of the 340B and IRA-related lawsuits, which could result in material financial adjustments.
- Hengrui Collaboration: Evaluate the strategic fit and potential milestone obligations ($14.3B) associated with the new Hengrui license agreement.